RxDoctor Payments Data

Karan Madan, MD

Interventional Pain Medicine · Sugar Land, TXNPI 1568410397

Payments from drug & device makers

$8,287in general payments, 2019–2025

Across 326 payments — averaging $25.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • Boston Scientific$1K
  • Collegium Pharmaceutical, Inc.$1K
  • Amgen$768
  • Nevro Corp.$676
  • Medtronic$550
  • plus $3K from 43 others

What the payments were for

  • Food & beverage$8,276100%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,287 in reported general payments places this provider in the 50th percentile of 287 interventional pain medicine providers in Texas.

See all interventional pain medicine providers in Texas

Medicare billing

Part B allowed, 2024
$443,865
Medicare patients
383
Services billed
16,347

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl77$53,418
Xtampza ErOxycodone Myristate35$20,563
NucyntaTapentadol Hcl30$16,173
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen804$15,360
Buprenorphine47$12,352
Diclofenac Sodium25$10,344
Pregabalin346$6,269
MovantikNaloxegol Oxalate15$6,162
Gabapentin489$5,336
Lidocaine53$3,401
Morphine Sulfate ErMorphine Sulfate38$2,917
Acetaminophen-CodeineAcetaminophen With Codeine144$2,630
Tizanidine Hcl390$2,398
Tramadol Hcl395$2,007
Duloxetine Hcl55$1,634

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er, Nucynta$1,043$90,153142 claims
Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate$40$12,64558 claims
Redhill Biopharma Inc.Movantik$48$6,16215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 287 interventional pain medicine providers in Texas.

Other interventional pain medicine in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →